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The gut microflora constitutes a dynamic and ecologically diverse environment. Normal 
microbial populations present in the gut provide an efficient barrier to invading 
microorganisms. Protection mechanisms involve the competition for nutrients and adhesion 
sites, the production of antimicrobial compounds, the lowering of intestinal pH through 
production of short-chain fatty acids and the stimulation of the immune system [1]. An 
imbalance in this bacterial consortium can favor the colonization by undesirable agents [2]. 
Therefore, the control of the bacterial balance in the gut of farm animals is interesting in order 
to limit the risk of infection and maximize performance.  
The easiest way to modulate bacterial populations is the use of antibiotics. However, on 
January 2006, European Union banned the feeding of all sub-therapeutic antibiotics to 
livestock for growth promotion purpose and there is a trend towards elimination or reduced 
use of these compounds in other countries. The animal feed industry must cope with this 
withdrawal and try to develop alternatives to antibiotics to modulate microflora (for a review, 
see [3]).  
For this purpose, the use of hen egg yolk antibodies (called IgY) has recently gained interest. 
Indeed, while the well-known prebiotics can stimulate bacteria of interest in the intestine, 
antibodies will instead limit the growth of undesirable targeted bacteria. Major source of 
human foodborne infections such as salmonellosis or campylobacteriosis, the hen could thus 
become an ally to fight these pathogens in the future, thanks to its ability to produce massive 
amounts of antibodies specific of targeted bacteria.  
This review article focuses on the use of IgY in therapy or prophylaxis of diseases in 
veterinary medicine as well as in the context of functional foods to modulate microflora in 
animal. Other aspects such as molecular properties of IgY or production procedures are 
reviewed in detail in Schade et al. [4].  
IMMUNOGLOBULIN Y (IgY) 
The hen transmits protective antibodies to its offspring via the egg, as observed in mammals 
via colostrum ingestion and/or placental transfer. Three classes of immunoglobulins are 
transferred in this way. IgA and IgM are present in the egg white at very low concentrations 
while large amounts of IgY (8-25 mg/ml) are present in the egg yolk [5]. These antibodies are 
specific of microbes the hen encountered during her life and are thus characteristic of the 
microbial environment of the henhouse. The natural transfer of antibody from hen to chick 
can be exploited to produce IgY specific of a given pathogen. Indeed, the concentration of 
IgY in the egg is proportional to that in maternal serum. Therefore, by immunizing laying 
hens with a specific target antigen, we can direct their immune system and lead to the export 
of high levels of specific IgY in their eggs [4]. Feeding these specific antibodies to other 
animals (chickens but also other species) can be seen as en extension of the passive maternal 
protection [6]. Furthermore, it can be speculated that these orally distributed IgY could allow 
a microbial control in the gut by binding, immobilising and inhibiting the growth of selected 
bacteria.  
PROMISING RESULTS OF IgY IN ANIMAL DIETS 
IgY are used in various research fields, including immunoassays, immunohistochemistry, 
diagnostics etc. [7]. Specific antibodies are also considered as a promising tool to modulate 
microflora.  
 
Treatment of intestinal infections  
Passive immunization is the most reported application of IgY in animal feed. It consists in a 
transfer from an individual to another of active humoral immunity through preformed antigen-
specific antibodies. The antibodies can be transmitted intravenously or orally. This last option 
is however widely preferred for the antibody treatment of infections localized in the digestive 
tract of animals.  
The mechanism of action of these antibodies at the intestinal level is not yet fully understood. 
Several in vitro studies showed that specific IgY have a growth inhibitory effect on targeted 
bacteria [8, 9]. For example, we demonstrated that specific IgY reduce the growth of 
Salmonella in a liquid medium. In the same study, anti-Salmonella IgY prevented the 
attachment of the bacterium at the intestinal Caco-2 cells [9]. These results indicate that IgY 
are able not only to alter the development of bacteria, but also to thwart their attachment to 
the intestinal epithelium. 
This antibacterial potential has been largely studied in veterinary research with the aim to 
prevent or treat gastrointestinal infections caused by enteric pathogens in a wide variety of 
animal species: chicken [10, 11, 12], calf [13, 14], duck [15], pig [16, 17, 18], sheep [19], 
rabbit [20] and even fishes [21, 22]. Although very promising effects have been obtained 
against various enteric pathogens, results reported are not always consistent. In a study 
conducted in our laboratory, specific IgY failed to reduce the cecal colonization by 
Salmonella Enteritidis and Salmonella Typhimurium in co-challenged broilers [11]. In this 
study, hyperimmune eggs were obtained from laying hens immunized using Salmonella 
Enteritidis and Salmonella Typhimurium outer membrane proteins. This led to high levels of 
IgY directed against the two serovars in egg yolks [23]. Powders were obtained from these 
hyperimmune eggs by freeze-drying the whole yolk. Salmonella-free one-day-old chicks 
received supplemented feed (5 % egg yolk powder) at five levels of concentration in specific 
IgY-enriched yolk powder (0 – 5%). Three days following the initiation of feed treatments, 
birds were co-challenged with 1 × 10
6
 cfu of Salmonella Enteritidis and Salmonella 
Typhimurium. Positive (challenged and untreated) and negative (unchallenged) control 
groups were considered. At 4 days post-infection, there was a trend towards a nearly 
significant difference (P < 0.1) between treatment groups concerning the Salmonella spp. 
cecal colonization. This trend was associated with a linear effect (P < 0.05) of specific IgY 
concentration. Nevertheless, this effect was not significant thereafter. In the same trial, we 
also observed an improvement in growth performance for the groups receiving the yolk 
enriched diets when compared with the untreated control group (P < 0.05). However, the 
challenged treated birds never reached the performance levels of unchallenged birds (P < 
0.05) and the growth performance enhancement was not associated with a specific IgY 
concentration effect.  
If IgY are able to remove some targeted bacteria in the gut, it could be expected that other 
groups or species could then develop because of substrate and adhesion sites availability. 
Therefore, it could be interesting to associate probiotics with an IgY treatment in order to 
colonize the empty space. Such combination products have been investigated with success in 
the recent years. Tellez et al. [24] reduced the colonization by Salmonella Enteritidis in 
broilers using a combination of Lactobacillus acidophilus and Streptococcus faecium (Avian 
Pac Plus, Loveland Industries Inc., Greeley, CO), and IgY directed against Salmonella 
Enteritidis, Salmonella Typhimurium, and Salmonella Heidelberg. Similarly, IgY orally 
distributed worked synergistically with probiotics (Lactobacillus acidophilus, Lactobacillus 
bulgaricum, Lactobacillus reuteri, and Bifidobacterium bifidum) to prevent Salmonella 
Enteritidis infection in challenged ducklings [15]. The synergistic effect is not always 
reported. The use of IgY combined with a probiotic mixture of Lactobacillus acidophilus, 
Lactobacillus casei, Enterococcus durans, and Bifidobacterium thermophilus (Primalac, Star 
Labs/Forage Research, Clarcksdate, MO) in broilers led to results similar to those obtained 
with the antibodies alone [10].  
The antimicrobial and growth promoter properties of hyperimmune egg yolk have been 
largely described, but the potential efficacy of nonimmune egg yolk has also been reported 
[11, 25]. It could be, at least in part, related to the presence of nonspecific IgY that are able to 
improve the intestinal immune system of the animal in a nonspecific way. Moreover, the egg 
yolk is rich in potentially beneficial components, both for the immune system of the animal 
(mainly immunoglobulins, but also low-density lipoproteins or sialyloligosaccharides) and for 
its growth (e.g. omega-3 fatty acids or phospholipids) [26].  
 
Modulation of the normal gut microflora 
Beyond the control of pathogens, antibodies could also be envisaged to modulate the normal 
gut microflora. This has been recently studied for example in ruminants, to decrease the risk 
of ruminal acidosis or to reduce methanogenesis in the rumen.  
Ruminal acidosis is a nutritional disorder commonly occuring in cattle fed with high-grain 
diets containing large amounts of rapidly fermentable carbohydrates. The resulting 
modification of the rumen microflora causes an accumulation of volatile fatty acids and 
lactate and a risk of acidosis. The consequences are an alteration in rumen fermentation 
patterns and in health of the animal [27]. Given the close link between the microbial balance 
in the rumen and the risk of acidosis, scientists developed means to manipulate this complex 
ecosystem. For example, an oral administration of lactate-utilizing bacteria (Megasphaera 
elsdenii) as a probiotic was successful in decreasing lactate concentration and increasing 
ruminal pH in the rumen of beef cattle rapidly changed from a forage-based to a grain-based 
diet [28]. On the opposite, vaccination against bacteria involved in the production of lactate 
(Streptococcus bovis) maintained higher pH and decreased lactate concentration in rumen 
[29]. IgY antibodies have also been investigated to control the ruminal ecosystem. Passive 
immunization through oral administration of IgY specific of Streptococcus bovis (lactate 
producer) or Fusobacterium necrophorum (involved in the development of liver abscesses in 
acidotic animals) reduced rumen concentrations of target bacteria in steers fed high-grain 
diets [30, 31]. The doses of antibody preparations used were as low as 2.5 mL per daily meal 
and were thus very low compared with the total volume of rumen. It was however sufficient 
to increase significantly the ruminal pH level with benefits on ruminal patterns. Indeed, both 
proteolytic and cellulolytic activities are pH-dependent so that fiber and protein digestibility 
might be improved by maintaining the rumen pH above 6.0 [32]. Moreover, such IgY 
treatment also exhibited a positive effect (P < 0.05) on feedlot performances [31, 33]. 
The use of passive immunization through IgY has also been proposed to control other ruminal 
bacteria such as methanogens. Over the last decades, researchers have explored a variety of 
approaches to decrease methane production in ruminants due to its contribution to the 
greenhouse effect and its cost as dietary energy to the ruminant [34]. Treatments using egg 
yolk antibodies have shown promising results in this area. Indeed, IgY specific of 
methanogenic bacteria (Methanobrevibacter smithii, Methanobrevibacter ruminantium and 
Methanosphaera stadtmanae) decreased CH4 production in vitro (P < 0.05) but this effect was 
only transient and by 24 h, CH4 levels in all treatments were similar (P > 0.05) to the 
untreated control [35]. However, these results suggest that IgY represents a promising tool of 
controlling the production of methane by cattle. 
CURRENT CHALLENGES AND FUTURE PROSPECTS 
There already exists some commercial products using the concept of passive immunization 
through IgY in the marketplace (e. g. Protimax®, Trouw Nutrition, Highland, IL ; Globigen®, 
EW Nutrition GmbH, Visbek, Germany) and others are currently in development in link with 
patented applications. Indeed, the use of egg proteins in animal feed is authorized by the 
current european legislation [36] and such egg-derived products are classified as GRAS 
(generally recognized as safe). Nevertheless, even if not prohibited, the use of egg proteins in 
animal feed, especially in the case of poultry feed, could still be rejected by consumers as are 
animal flour in cattle feed since the mad cow crisis. Other aspects could explain why a wide 
distribution of hyperimmune egg-derived products to commercial farm animals remains a 
difficult goal to achieve.   
As discussed above, the results reported for these passive immunization strategies are not 
always consistent. This can be attributed to the variability in protocols investigating these 
effects, including both in vitro and in vivo methods, and studying the effects of IgY on a 
variety of bacterial agents, in various animal species.  
Farmers might be interested to control multiple gut microbes. Among them, there are 
infectious agents but also bacteria composing the normal gut microflora that we could want to 
regulate. Nevertheless, most studies have been made against a certain bacterium in order to 
control its development and colonization. The feed industry would benefit more of antibodies 
preparations targeting a variety of bacteria. Enlarging the activity spectrum of products would 
promote their commercial application [37]. For example, we have been able to produce IgY 
simultaneously directed against several Salmonella serovars in the same egg yolk [23] with a 
proven efficacy in in vitro models [9]. In some cases (e. g. with Salmonella), it is possible to 
take advantage of the cross-reactivity especially when immunizing the hens with isolated 
proteins shared by several serovars [23]. But in most of the cases, the specificity of developed 
IgY to a particular epitope will induce the need to produce IgY on a case-by-case basis with 
obvious cost consequences [6].   
The form in which the antibodies are delivered to animals is also an area that requires further 
development. Indeed, administer antibodies in a stomach-resistant formula is important in 
order to prevent inactivation by the acidic pH of the stomach or by proteases before the 
intestine. Studies conducted with broilers [38, 39, 40] have shown that IgY activity remained 
detectable at the end of the gut. Moreover, the proteo-lipidic matrix of the egg yolk is 
effective in protecting the antibodies from the digestive process both in vitro [39, 41] and in 
vivo [39, 40]. Nevertheless, even though IgY were protected in the egg yolk proteo-lipidic 
matrix, this protection seems to be insufficient with regard to the decrease of activity [40]. 
The same problems of gastric degradation have been reported in pigs [42]. It is somewhat 
different when looking for an activity in the rumen of polygastric species.   
Microencapsulation may be an effective method for protecting IgY from gastrointestinal 
inactivation [42, 43, 44, 45]. The proposed encapsulation procedures often involve pH-
sensible matrix. The release of antibodies to the place where their action is desired in the 
digestive tract of the animal will be a crucial point for the effectiveness of these protecting 
products. This is particularly true with regard to poultry, where the role of the crop, in which 
the pH may be close to that of the intestine, cannot be neglected. 
In conclusion, IgY may be a useful and attractive alternative to antibiotics in order to 
modulate microbial populations in the gut of farm animals. Results are already promising 
including beneficial impacts on animal performances and health and possible actions where 
this tool could be used is still vast. This technology, even if needing some further research 
particularly on the protection-release aspect, is thus likely to be of great value to the animal 
feed industry in the coming years.  
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